CCR1 as a target for multiple myeloma

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 9, 2011, Pages 1037-1047

  Vallet, Sonia ^a,b   Anderson, Kenneth C ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CCL3; CCR1; CCR5; Chemokine; Myeloma; Osteoblast; Osteoclast; Osteolytic bone disease

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; ANTISENSE OLIGONUCLEOTIDE; AZD 4818; BORTEZOMIB; CCX 354; CCX 721; CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR1 ANTAGONIST; CHEMOKINE RECEPTOR CCR5; CP 481715; CYTOKINE; CYTOKINE ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 6; LENALIDOMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA ANTIBODY; METHOTREXATE; MLN 3897; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NEUTRALIZING ANTIBODY; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; SOTATERCEPT; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BONE ATROPHY; BONE MARROW CELL; BONE REMODELING; CARCINOGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DOWN REGULATION; DRUG RECEPTOR BINDING; DRUG TARGETING; HEMATOPOIESIS; HUMAN; IMMUNOMODULATION; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYELOMA CELL; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; TUMOR GROWTH; TUMOR VASCULARIZATION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOKINE CCL3; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; MULTIPLE MYELOMA; OSTEOLYSIS; RECEPTORS, CCR1;

EID: 80051761546     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.586634     Document Type: Review

References (92)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics. CA Cancer J Clin 2010;60:277-300
2. Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585-98 This review describes exhaustively the pathogenesis of multiple myeloma with a special focus on the critical role played by the tumor microenvironment.
3. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20
4. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996;87:1104-12
5. Abe M, Hiura K, Wilde J, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion. Blood 2004;104:2484-91
6. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: Therapeutic implications. Blood 2005;105:1383-95
7. Edwards CM, Edwards JR, Lwin ST, et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 2008;111:2833-42
8. Rosenblatt J, Vasir B, Uhl L, et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 2011;117:393-402
9. Giuliani N, Bataille R, Mancini C, et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98:3527-33
10. Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 2004;32:290-2
11. Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 2002;100:2195-202
12. Lentzsch S, Gries M, Janz M, et al. Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003;101:3568-73
13. Rollins BJ. Chemokines. Blood 1997;90:909-28
14. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610-21
15. Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002;13:455-81
16. Zlotnik A, Yoshie O. Chemokines: A new classification system and their role in immunity. Immunity 2000;12:121-7
17. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52:145-76 This manuscript provides a critical overview on the chemokine system, including differences in murine and human chemokine biologies.
18. Foxman EF, Campbell JJ, Butcher EC. Multistep navigation and the combinatorial control of leukocyte chemotaxis. J Cell Biol 1997;139:1349-60
19. Haribabu B, Zhelev DV, Pridgen BC, et al. Chemoattractant receptors activate distinct pathways for chemotaxis and secretion. Role of G-protein usage. J Biol Chem 1999;274:37087-92
20. Rabin RL, Park MK, Liao F, et al. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J Immunol 1999;162:3840-50
21. Abdi R, Means TK, Ito T, et al. Differential role of CCR2 in islet and heart allograft rejection: Tissue specificity of chemokine/chemokine receptor function in vivo. J Immunol 2004;172:767-75
22. Wang CL, Sun BS, Tang Y, et al. CCR1 knockdown suppresses human non-small cell lung cancer cell invasion. J Cancer Res Clin Oncol 2009;135:695-701
23. Kitamura T, Fujishita T, Loetscher P, et al. Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proc Natl Acad Sci USA 2010;107:13063-8
24. Godessart N. Chemokine receptors: Attractive targets for drug discovery. Ann N Y Acad Sci 2005;1051:647-57
25. Saeki T, Naya A. CCR1 chemokine receptor antagonist. Curr Pharm Des 2003;9:1201-8
26. Su S, Mukaida N, Wang J, et al. Inhibition of immature erythroid progenitor cell proliferation by macrophage inflammatory protein-1alpha by interacting mainly with a C-C chemokine receptor, CCR1. Blood 1997;90:605-11
27. Meucci O, Fatatis A, Simen AA, et al. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci USA 1998;95:14500-5
28. Yang M, Mailhot G, MacKay CA, et al. Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: A key role for CCL9 (MIP-1gamma) in osteoclastogenesis in vivo and in vitro. Blood 2006;107:2262-70
29. Vallet S, Raje N, Ishitsuka K, et al. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 2007;110:3744-52
30. Sallusto F, Palermo B, Lenig D, et al. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 1999;29:1617-25
31. Chou CC, Fine JS, Pugliese-Sivo C, et al. Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL-60 cells: Antagonism of hCCR1 activation by MIP-1beta. Br J Pharmacol 2002;137:663-75
32. Nibbs RJ, Yang J, Landau NR, et al. LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity. J Biol Chem 1999;274:17478-83
33. Menten P, Struyf S, Schutyser E, et al. The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine. J Clin Invest 1999;104:R1-5
34. Struyf S, Menten P, Lenaerts JP, et al. Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils. Eur J Immunol 2001;31:2170-8
35. Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005;307:1434-40
36. Moller C, Stromberg T, Juremalm M, et al. Expression and function of chemokine receptors in human multiple myeloma. Leukemia 2003;17:203-10
37. Oba Y, Lee JW, Ehrlich LA, et al. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 2005;33:272-8
38. Menu E, De Leenheer E, De Raeve H, et al. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: A study in the 5TMM model. Clin Exp Metastasis 2006;23:291-300
39. Trentin L, Miorin M, Facco M, et al. Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. Br J Haematol 2007;138:594-602
40. Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001;108:1833-41 This study describes for the first time the important role of CCL3 in the pathogenesis of MM-induced bone disease and tumor growth.
41. Han JH, Choi SJ, Kurihara N, et al. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001;97:3349-53
42. Yu X, Huang Y, Collin-Osdoby P, et al. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res 2004;19:2065-77
43. Hwang J, Son KN, Kim CW, et al. Human CC chemokine CCL23, a ligand for CCR1, induces endothelial cell migration and promotes angiogenesis. Cytokine 2005;30:254-63
44. Honczarenko M, Le Y, Swierkowski M, et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006;24:1030-41
45. Mateo T, Abu Nabah YN, Abu Taha M, et al. Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J Immunol 2006;176:5577-86
46. Veillard NR, Braunersreuther V, Arnaud C, et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006;188:51-8
47. Cao Y, Luetkens T, Kobold S, et al. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp Hematol 2010;38:860-7
48. Masih-Khan E, Trudel S, Heise C, et al. MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood 2006;108:3465-71
49. Abe M, Hiura K, Ozaki S, et al. Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production. J Bone Miner Metab 2009;27:16-23
50. Vallet S, Pozzi S, Patel K, et al. A Novel role for CCL3 (MIP-1alpha) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia 2011 [Epub ahead of print]
51. Richardson RM, Pridgen BC, Haribabu B, et al. Regulation of the human chemokine receptor CCR1. Cross-regulation by CXCR1 and CXCR2. J Biol Chem 275:9201-8, 2000
52. Shahrara S, Amin MA, Woods JM, et al. Chemokine receptor expression and in vivo signaling pathways in the joints of rats with adjuvant-induced arthritis. Arthritis Rheum 48:3568-83, 2003
53. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671-75
54. Kitamura T, Kometani K, Hashida H, et al. SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat Genet 2007;39:467-75
55. Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110:1860-7
56. Kim IS, Ryang YS, Kim YS, et al. Leukotactin-1-induced ERK activation is mediated via Gi/Go protein/PLC/PKC delta/Ras cascades in HOS cells. Life Sci 2003;73:447-59
57. Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003;102:311-19
58. Tsubaki M, Kato C, Manno M, et al. Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways. Mol Cell Biochem 2007;304:53-60
59. Vincent C, Findlay DM, Welldon KJ, et al. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 2009;24:1434-49
60. Gao JL, Wynn TA, Chang Y, et al. Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J Exp Med 1997;185:1959-68
61. Portier M, Zhang XG, Caron E, et al. gamma-Interferon in multiple myeloma: Inhibition of interleukin-6 (IL-6)- dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood 1993;81:3076-82
62. Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010;10:155-67
63. Vande Broek I, Leleu X, Schots R, et al. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: The association with disease activity and survival. Haematologica 2006;91:200-6
64. De Vos J, Couderc G, Tarte K, et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 2001;98:771-80
65. Magrangeas F, Nasser V, Avet-Loiseau H, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 2003;101:4998-5006
66. Uneda S, Hata H, Matsuno F, et al. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol 2003;120:53-5
67. Dizdar O, Barista I, Kalyoncu U, et al. Biochemical markers of bone turnover in diagnosis of myeloma bone disease. Am J Hematol 2007;82:185-91
68. Hashimoto T, Abe M, Oshima T, et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 2004;125:38-41
69. Politou M, Terpos E, Anagnostopoulos A, et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2004;126:686-9
70. Terpos E, Politou M, Szydlo R, et al. Serum levels of macrophage inflammatory protein-1 alpha (MIP- 1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003;123:106-9
71. Roussou M, Tasidou A, Dimopoulos MA, et al. Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia 2009;23:2177-81
72. Alsina M, Boyce B, Devlin RD, et al. Development of an in vivo model of human multiple myeloma bone disease. Blood 1996;87:1495-501
73. Liang M, Mallari C, Rosser M, et al. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem 2000;275:19000-8
74. Oyajobi B, Dairaghi D, Gupta A, et al. CCR1 Blockade by An Orally-Available CCR1 Antagonist Reduces Tumor Burden and Osteolysis In Vivo In a Mouse Model of Myeloma Bone Disease Blood, ASH 2010:3000, 2010
75. Tassone P, Neri P, Carrasco DR, et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005;106:713-16
76. Reuss R, Schreiber V, Klein A, et al. No significant effect of orally administered chemokine receptor 1 antagonist on intercellular adhesion molecule-3 expression in relapsing-remitting multiple sclerosis patients. Mult Scler 2010;16:366-9
77. Norman P. AZD-4818, a chemokine CCR1 antagonist: WO2008103126 and WO2009011653. Expert Opin Ther Pat 2009;19:1629-33
78. Haringman JJ, Kraan MC, Smeets TJ, et al. Chemokine blockade and chronic inflammatory disease: Proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:715-21
79. Britschgi MR, Link A, Lissandrin TK, et al. Dynamic modulation of CCR7 expression and function on naive T lymphocytes in vivo. J Immunol 2008;181:7681-8
80. Jimenez F, Quinones MP, Martinez HG, et al. CCR2 plays a critical role in dendritic cell maturation: Possible role of CCL2 and NF-kappa B. J Immunol 2010;184:5571-81
81. Vergunst CE, Gerlag DM, Lopatinskaya L, et al. Modulation of CCR2 in rheumatoid arthritis: A double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2008;58:1931-9
82. Johnston B, Kim CH, Soler D, et al. Differential chemokine responses and homing patterns of murine TCR alpha beta NKT cell subsets. J Immunol 2003;171:2960-9
83. Mestas J, Hughes CC. Of mice and not men: Differences between mouse and human immunology. J Immunol 2004;172:2731-8
84. Zhang S, Youn BS, Gao JL, et al. Differential effects of leukotactin-1 and macrophage inflammatory protein-1 alpha on neutrophils mediated by CCR1. J Immunol 1999;162:4938-42
85. Gladue RP, Cole SH, Roach ML, et al. The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice. J Immunol 2006;176:3141-8
86. Zhang Y, Yao F, Yao X, et al. Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Oncol Rep 2009;21:1113-21
87. Chuang JY, Yang WH, Chen HT, et al. CCL5/CCR5 axis promotes the motility of human oral cancer cells. J Cell Physiol 2009;220:418-26
88. Gladue RP, Tylaska LA, Brissette WH, et al. CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J Biol Chem 2003;278:40473-80
89. Merritt JR, Liu J, Quadros E, et al. Novel pyrrolidine ureas as C-C chemokine receptor 1 (CCR1) antagonists. J Med Chem 2009;52:1295-301
90. Clucas AT, Shah A, Zhang YD, et al. Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715. Clin Pharmacokinet 2007;46:757-66
91. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-5
92. Zheng B, Wiklund F, Gharizadeh B, et al. Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients. Anticancer Res 2006;26:3669-74